Received Mar 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Pediatric dose given; Pediatric dose given; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of underdose in a adult patient who received HBV (Engerix B pediatric) for prophylaxis. Previously administered products included Engerix b (received 1st dose of Engerix b in an unknown date). On an unknown date, the patient received the 2nd dose of Engerix B pediatric. On an unknown date, an unknown time after receiving Engerix B pediatric, the patient experienced underdose (Verbatim: Pediatric dose given) and adult use of a child product (Verbatim: Pediatric dose given). The outcome of the underdose and adult use of a child product were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 05-MAR-2025 The pharmacist that an adult patient received their second Engerix-B dose as a Pediatric dose which led to underdose and adult use of a child product. They had no information about the event, dose or patient, The Vaccine Administration Facility is the same as Primary Reporter.